| Year |
Citation |
Score |
| 2020 |
Banik I, Cheng PF, Dooley CM, Travnickova J, Merteroglu M, Dummer R, Patton EE, Busch-Nentwich EM, Levesque MP. NRAS melanoma tumor formation is reduced by p38-MAPK14 activation in zebrafish models and NRAS-mutated human melanoma cells. Pigment Cell & Melanoma Research. PMID 32910840 DOI: 10.1111/Pcmr.12925 |
0.367 |
|
| 2020 |
Rabbie R, Ansari-Pour N, Cast O, Lau D, Scott F, Welsh SJ, Parkinson C, Khoja L, Moore L, Tullett M, Wong K, Ferreira I, Gómez JMM, Levesque M, Gallagher FA, et al. Multi-site clonality analysis uncovers pervasive heterogeneity across melanoma metastases. Nature Communications. 11: 4306. PMID 32855398 DOI: 10.1038/S41467-020-18060-0 |
0.328 |
|
| 2020 |
Teh JL, Erkes DA, Cheng PF, Tiago M, Wilski NA, Field CO, Chervoneva I, Levesque MP, Xu X, Dummer R, Aplin AE. Activation of CD8+ T cells contributes to anti-tumor effects of CDK4/6 inhibitors plus MEK inhibitors. Cancer Immunology Research. PMID 32661093 DOI: 10.1158/2326-6066.Cir-19-0743 |
0.348 |
|
| 2020 |
Lazar I, Fabre B, Feng Y, Khateb A, Turko P, Martinez-Gomez MJ, Frederick DT, Levesque MP, Feld L, Zhang G, Zhang T, James B, Shklover J, Avitan Hersh E, Livneh I, et al. SPANX control of Lamin A/C modulates nuclear architecture and promotes melanoma growth. Molecular Cancer Research : McR. PMID 32571981 DOI: 10.1158/1541-7786.Mcr-20-0291 |
0.371 |
|
| 2020 |
Vandamme N, Denecker G, Bruneel K, Blancke G, Akay Ö, Taminau J, De Coninck J, De Smedt E, Skrypek N, Van Loocke W, Wouters J, Nittner D, Köhler C, Darling DS, Cheng PF, ... ... Levesque MP, et al. The EMT transcription factor ZEB2 promotes proliferation of primary and metastatic melanoma while suppressing an invasive, mesenchymal-like phenotype. Cancer Research. PMID 32503808 DOI: 10.1158/0008-5472.Can-19-2373 |
0.352 |
|
| 2020 |
Nguyen MQ, Teh JLF, Purwin TJ, Chervoneva I, Davies MA, Nathanson KL, Cheng PF, Levesque MP, Dummer R, Aplin AE. Targeting PHGDH upregulation reduces glutathione levels and re-sensitizes resistant NRAS mutant melanoma to MEK inhibition. The Journal of Investigative Dermatology. PMID 32389536 DOI: 10.1016/J.Jid.2020.02.047 |
0.355 |
|
| 2020 |
Kaufmann C, Kempf W, Mangana J, Cheng P, Emberger M, Lang R, Kaiser AK, Lattmann E, Levesque M, Dummer R, Koelblinger P. The role of Cyclin D1 and Ki-67 in the development and prognostication of thin melanoma. Histopathology. PMID 32374893 DOI: 10.1111/His.14139 |
0.321 |
|
| 2020 |
Uka R, Britschgi C, Krättli A, Matter C, Mihic D, Okoniewski MJ, Gualandi M, Stupp R, Cinelli P, Dummer R, Levesque MP, Shakhova O. Temporal activation of WNT/β-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth. Oncogene. PMID 32238882 DOI: 10.1038/S41388-020-1267-7 |
0.368 |
|
| 2020 |
Cheng P, Levesque MP, Dummer R, Mangana J. Targeting complex, adaptive responses in melanoma therapy. Cancer Treatment Reviews. 86: 101997. PMID 32179238 DOI: 10.1016/J.Ctrv.2020.101997 |
0.337 |
|
| 2019 |
Wenzina J, Holzner S, Puujalka E, Cheng PF, Forsthuber A, Neumüller K, Schossleitner K, Lichtenberger BM, Levesque MP, Petzelbauer P. Inhibition of p38/MK2 signaling prevents vascular invasion of melanoma. The Journal of Investigative Dermatology. PMID 31622599 DOI: 10.1016/J.Jid.2019.08.451 |
0.383 |
|
| 2019 |
Nagler A, Vredevoogd DW, Alon M, Cheng PF, Trabish S, Kalaora S, Arafeh R, Goldin V, Levesque MP, Peeper DS, Samuels Y. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance towards MEK inhibition in NRAS mutant melanoma. Pigment Cell & Melanoma Research. PMID 31549767 DOI: 10.1111/Pcmr.12825 |
0.395 |
|
| 2019 |
Freiberger SN, Morand GB, Turko P, Wager U, Dummer R, Hüllner M, Holzmann D, Rupp NJ, Levesque MP. Morpho-Molecular Assessment Indicates New Prognostic Aspects and Personalized Therapeutic Options in Sinonasal Melanoma. Cancers. 11. PMID 31500314 DOI: 10.3390/Cancers11091329 |
0.345 |
|
| 2019 |
Aloia A, Müllhaupt D, Chabbert CD, Eberhart T, Flueckiger S, Vukolic A, Eichhoff OM, Irmisch A, Alexander LT, Scibona E, Frederick DT, Miao B, Tian T, Cheng C, Kwong LN, ... ... Levesque MP, et al. A fatty acid oxidation-dependent metabolic shift regulates the adaptation of -mutated melanoma to MAPK inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31375515 DOI: 10.1158/1078-0432.Ccr-19-0253 |
0.344 |
|
| 2019 |
Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, Li Z, Kazakoff SH, Burke H, Dodds TJ, Patch AM, Nones K, Tembe V, Shang P, van der Weyden L, ... ... Levesque MP, et al. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications. 10: 3163. PMID 31320640 DOI: 10.1038/S41467-019-11107-X |
0.317 |
|
| 2019 |
Paulitschke V, Eichhoff O, Gerner C, Paulitschke P, Bileck A, Mohr T, Cheng PF, Leitner A, Guenova E, Saulite I, Freiberger SN, Irmisch A, Knapp B, Zila N, Chatziisaak TP, ... ... Levesque MP, et al. Proteomic identification of a marker signature for MAPKi resistance in melanoma. The Embo Journal. e95874. PMID 31267558 DOI: 10.15252/Embj.201695874 |
0.378 |
|
| 2019 |
Tuncer E, Calçada RR, Zingg D, Varum S, Cheng P, Freiberger SN, Deng CX, Kleiter I, Levesque MP, Dummer R, Sommer L. SMAD signaling promotes melanoma metastasis independently of phenotype switching. The Journal of Clinical Investigation. 130. PMID 31039140 DOI: 10.1172/Jci94295 |
0.374 |
|
| 2019 |
Varum S, Baggiolini A, Zurkirchen L, Atak ZK, Cantù C, Marzorati E, Bossart R, Wouters J, Häusel J, Tuncer E, Zingg D, Veen D, John N, Balz M, Levesque MP, et al. Yin Yang 1 Orchestrates a Metabolic Program Required for Both Neural Crest Development and Melanoma Formation. Cell Stem Cell. 24: 637-653.e9. PMID 30951662 DOI: 10.1016/J.Stem.2019.03.011 |
0.347 |
|
| 2019 |
Poźniak J, Nsengimana J, Laye JP, O'Shea SJ, Diaz JMS, Droop AP, Filia A, Harland M, Davies JR, Mell T, Randerson-Moor JA, Muralidhar S, Hogan SA, Freiberger SN, Levesque MP, et al. Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma. Cancer Research. PMID 30773503 DOI: 10.1158/0008-5472.Can-18-2864 |
0.327 |
|
| 2019 |
Sand J, Fenini G, Grossi S, Hennig P, Di Filippo M, Levesque M, Werner S, French LE, Beer HD. The NLRP1 Inflammasome Pathway Is Silenced in Cutaneous Squamous Cell Carcinoma. The Journal of Investigative Dermatology. 139: 1788-1797.e6. PMID 30738816 DOI: 10.1016/J.Jid.2019.01.025 |
0.32 |
|
| 2019 |
Cheng P, Freiberger S, Panetti C, Irmisch A, Dummer R, Levesque M. Integrative RNAseq and target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors Annals of Oncology. 30: v547. DOI: 10.1093/Annonc/Mdz255.028 |
0.329 |
|
| 2018 |
Clocchiatti A, Ghosh S, Procopio MG, Mazzeo L, Bordignon P, Ostano P, Goruppi S, Bottoni G, Katarkar A, Levesque M, Kölblinger P, Dummer R, Neel V, Özdemir BC, Dotto GP. Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation. The Journal of Clinical Investigation. PMID 30395538 DOI: 10.1172/Jci99159 |
0.33 |
|
| 2018 |
Pich C, Meylan P, Mastelic-Gavillet B, Nguyen NT, Loyon R, Trang BK, Moser H, Moret C, Goepfert C, Hafner J, Levesque MP, Romero P, Jandus C, Michalik L. Induction of paracrine signaling in metastatic melanoma cells by PPARγ agonist rosiglitazone activates stromal cells and enhances tumor growth. Cancer Research. PMID 30185551 DOI: 10.1158/0008-5472.Can-18-0912 |
0.354 |
|
| 2018 |
Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, Karras P, Brown D, Chang YH, Debiec-Rychter M, Adriaens C, Radaelli E, Wolter P, Bechter O, Dummer R, ... Levesque M, et al. Toward Minimal Residual Disease-Directed Therapy in Melanoma. Cell. PMID 30017245 DOI: 10.1016/J.Cell.2018.06.025 |
0.381 |
|
| 2018 |
Zingg D, Debbache J, Peña-Hernández R, Antunes AT, Schaefer SM, Cheng PF, Zimmerli D, Haeusel J, Calçada RR, Tuncer E, Zhang Y, Bossart R, Wong KK, Basler K, Dummer R, ... ... Levesque MP, et al. EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation. Cancer Cell. 34: 69-84.e14. PMID 30008323 DOI: 10.1016/J.Ccell.2018.06.001 |
0.359 |
|
| 2018 |
Hogan SA, Levesque MP, Cheng PF. Melanoma Immunotherapy: Next-Generation Biomarkers. Frontiers in Oncology. 8: 178. PMID 29896449 DOI: 10.3389/Fonc.2018.00178 |
0.333 |
|
| 2018 |
García-Martín AB, Zwicky P, Gruber T, Matti C, Moalli F, Stein JV, Francisco D, Enzmann G, Levesque MP, Hewer E, Lyck R. VLA-4 mediated adhesion of melanoma cells on the blood-brain barrier is the critical cue for melanoma cell intercalation and barrier disruption. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 271678X18775887. PMID 29762071 DOI: 10.1177/0271678X18775887 |
0.324 |
|
| 2018 |
Sinnberg T, Niessner H, Levesque MP, Dettweiler C, Garbe C, Busch C. Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells. Biology Open. 7. PMID 29716947 DOI: 10.1242/Bio.032656 |
0.377 |
|
| 2018 |
Brüggen MC, Mangana J, Irmisch A, French LE, Levesque MP, Cheng PF, Dummer R. Methadone - not a magic bullet in melanoma therapy. Experimental Dermatology. PMID 29577418 DOI: 10.1111/Exd.13543 |
0.337 |
|
| 2018 |
Zila N, Bileck A, Muqaku B, Janker L, Eichhoff OM, Cheng PF, Dummer R, Levesque MP, Gerner C, Paulitschke V. Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases. Clinical Proteomics. 15: 13. PMID 29541007 DOI: 10.1186/S12014-018-9189-X |
0.334 |
|
| 2018 |
Sinnberg T, Levesque MP, Krochmann J, Cheng PF, Ikenberg K, Meraz-Torres F, Niessner H, Garbe C, Busch C. Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype. Molecular Cancer. 17: 59. PMID 29454361 DOI: 10.1186/S12943-018-0773-5 |
0.334 |
|
| 2018 |
Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nature Medicine. PMID 29309059 DOI: 10.1038/Nm.4466 |
0.323 |
|
| 2018 |
Koelblinger P, Levesque MP, Kaufmann C, Sülberg H, Hinke A, Hoffmann M, Brunner G, Dummer R. A prognostic gene-signature based identification of high-risk thin melanomas. Journal of Clinical Oncology. 36: e21575-e21575. DOI: 10.1200/Jco.2018.36.15_Suppl.E21575 |
0.304 |
|
| 2018 |
Hurkmans D, Verdegaal EME, Schindler SA, Basak EA, Heuvel DMAvd, Wijn Rd, Ruijtenbeek R, Groten JP, Dummer R, Koolen SLW, Welters MJP, Mathijssen RHJ, Kapiteijn E, Aerts JGJV, Levesque MP, et al. Blood-based multiplex kinase activity profiling as a predictive marker for clinical response to checkpoint blockade in advanced melanoma. Journal of Clinical Oncology. 36: 9579-9579. DOI: 10.1200/Jco.2018.36.15_Suppl.9579 |
0.305 |
|
| 2018 |
Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B. Abstract 566: High dimensional single cell analysis predicts response to anti-PD-1 immunotherapy Cancer Research. 78: 566-566. DOI: 10.1158/1538-7445.Am2018-566 |
0.318 |
|
| 2017 |
Silina K, Soltermann A, Movahedian Attar F, Casanova R, Uckeley ZM, Thut H, Wandres M, Isajevs S, Cheng PF, Curioni Fontecedro A, Foukas P, Levesque MP, Moch H, Linē A, van den Broek M. Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Research. PMID 29279354 DOI: 10.1158/0008-5472.Can-17-1987 |
0.323 |
|
| 2017 |
Qu Y, Olsen JR, Yuan X, Cheng PF, Levesque MP, Brokstad KA, Hoffman PS, Oyan AM, Zhang W, Kalland KH, Ke X. Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer. Nature Chemical Biology. PMID 29083417 DOI: 10.1038/Nchembio.2510 |
0.309 |
|
| 2017 |
Xue G, Kohler R, Tang F, Hynx D, Wang Y, Orso F, Prêtre V, Ritschard R, Hirschmann P, Cron P, Roloff T, Dummer R, Mandalà M, Bichet S, Genoud C, ... ... Levesque MP, et al. mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. Oncotarget. 8: 69204-69218. PMID 29050198 DOI: 10.18632/Oncotarget.18213 |
0.379 |
|
| 2017 |
Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, ... ... Levesque M, et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nature Communications. 8: 592. PMID 28928380 DOI: 10.1038/S41467-017-00608-2 |
0.334 |
|
| 2017 |
Dummer R, Ramelyte E, Schindler S, Thürigen O, Levesque MP, Koelblinger P. MEK inhibition and immune responses in advanced melanoma. Oncoimmunology. 6: e1335843. PMID 28919996 DOI: 10.1080/2162402X.2017.1335843 |
0.354 |
|
| 2017 |
Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ, Viswanathan SR, Chattopadhyay S, Tamayo P, Yang WS, Rees MG, ... ... Levesque MP, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. PMID 28678785 DOI: 10.1038/Nature23007 |
0.321 |
|
| 2017 |
Smith MP, Rowling EJ, Miskolczi Z, Ferguson J, Spoerri L, Haass NK, Sloss O, McEntegart S, Arozarena I, von Kriegsheim A, Rodriguez J, Brunton H, Kmarashev J, Levesque MP, Dummer R, et al. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. Embo Molecular Medicine. PMID 28606996 DOI: 10.15252/Emmm.201607156 |
0.375 |
|
| 2017 |
Mangana J, Cheng PF, Kaufmann C, Amann VC, Frauchiger AL, Stögner V, Held U, von Moos R, Michielin O, Braun RP, Levesque MP, Goldinger SM, Dummer R. Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma Research. PMID 28509765 DOI: 10.1097/Cmr.0000000000000359 |
0.302 |
|
| 2017 |
Levesque MP, Cheng PF, Raaijmakers MI, Saltari A, Dummer R. Metastatic melanoma moves on: translational science in the era of personalized medicine. Cancer Metastasis Reviews. PMID 28321632 DOI: 10.1007/S10555-017-9658-0 |
0.328 |
|
| 2017 |
Behera R, Kaur A, Webster MR, Kim S, Ndoye A, Kugel CH, Alicea GM, Wang JX, Ghosh K, Cheng PF, Lisanti S, Marchbank K, Dang V, Levesque MP, Dummer R, et al. Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of Klotho. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28232477 DOI: 10.1158/1078-0432.Ccr-17-0201 |
0.317 |
|
| 2017 |
Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C. The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition. European Journal of Cancer (Oxford, England : 1990). PMID 28169047 DOI: 10.1016/J.Ejca.2016.12.010 |
0.363 |
|
| 2017 |
Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition. European Journal of Cancer (Oxford, England : 1990). PMID 28162869 DOI: 10.1016/J.Ejca.2016.12.012 |
0.358 |
|
| 2017 |
Antsiferova M, Piwko-Czuchra A, Cangkrama M, Wietecha M, Sahin D, Birkner K, Amann VC, Levesque M, Hohl D, Dummer R, Werner S. Activin promotes skin carcinogenesis by attraction and reprogramming of macrophages. Embo Molecular Medicine. 9: 27-45. PMID 27932444 DOI: 10.15252/Emmm.201606493 |
0.326 |
|
| 2017 |
Dhar S, Chiovaro F, Tanos T, Hejhal T, Heilemariam S, Kelm J, Irmisch A, Levesque M. Abstract 5781: Establishment of a 3Dex-vivoassay as a preclinical drug testing platform for personalized cancer therapy Cancer Research. 77: 5781-5781. DOI: 10.1158/1538-7445.Am2017-5781 |
0.313 |
|
| 2016 |
Farsam V, Basu A, Gatzka M, Treiber N, Schneider LA, Mulaw MA, Lucas T, Kochanek S, Dummer R, Levesque MP, Wlaschek M, Scharffetter-Kochanek K. Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migration. Oncotarget. PMID 27907906 DOI: 10.18632/Oncotarget.13446 |
0.37 |
|
| 2016 |
Raaijmakers MI, Widmer DS, Narechania A, Eichhoff O, Freiberger SN, Wenzina J, Cheng PF, Mihic-Probst D, Desalle R, Dummer R, Levesque MP. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance. Oncotarget. PMID 27791198 DOI: 10.18632/Oncotarget.12848 |
0.342 |
|
| 2016 |
Czyż M, Toma M, Gajos-Michniewicz A, Majchrzak K, Hoser G, Szemraj J, Nieborowska-Skorska M, Cheng P, Gritsyuk D, Levesque M, Dummer R, Sliwinski T, Skorski T. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. Oncotarget. PMID 27705909 DOI: 10.18632/Oncotarget.12270 |
0.342 |
|
| 2016 |
Huber R, Meier B, Otsuka A, Fenini G, Satoh T, Gehrke S, Widmer D, Levesque MP, Mangana J, Kerl K, Gebhardt C, Fujii H, Nakashima C, Nonomura Y, Kabashima K, et al. Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages. Scientific Reports. 6: 29914. PMID 27426915 DOI: 10.1038/Srep29914 |
0.325 |
|
| 2016 |
Claps G, Cheli Y, Zhang T, Scortegagna M, Lau E, Kim H, Qi J, Li JL, James B, Dzung A, Levesque MP, Dummer R, Hayward NK, Bosenberg M, Brown KM, et al. A Transcriptionally Inactive ATF2 Variant Drives Melanomagenesis. Cell Reports. PMID 27210757 DOI: 10.1016/J.Celrep.2016.04.072 |
0.371 |
|
| 2016 |
Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP, Dummer R, Frederick DT, Flaherty KT, Cooper ZA, Wargo JA, et al. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell. 29: 270-284. PMID 26977879 DOI: 10.1016/J.Ccell.2016.02.003 |
0.37 |
|
| 2016 |
Paulitschke V, Eichhoff O, Cheng PF, Levesque MP, Höller C. Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma. Current Opinion in Oncology. PMID 26742019 DOI: 10.1097/Cco.0000000000000261 |
0.358 |
|
| 2016 |
Flueckiger S, Aloia A, Frischknecht L, Tuozzo A, Croci D, Shakhova O, Britschgi C, Dummer R, Levesque MP, Krek W. Abstract 300: Inhibition of oncogenic MAPK signaling in melanoma triggers SOX2-dependent adaptive drug resistance Cancer Research. 76: 300-300. DOI: 10.1158/1538-7445.Am2016-300 |
0.371 |
|
| 2015 |
Rolfs F, Huber M, Kuehne A, Kramer S, Haertel E, Muzumdar S, Wagner J, Tanner Y, Böhm F, Smola S, Zamboni N, Levesque MP, Dummer R, Beer HD, Hohl D, et al. Nrf2 Activation Promotes Keratinocyte Survival during Early Skin Carcinogenesis via Metabolic Alterations. Cancer Research. PMID 26530903 DOI: 10.1158/0008-5472.Can-15-0614 |
0.323 |
|
| 2015 |
Levesque MP, Dummer R, Beerenwinkel N. Perturbing resistance: a network perspective. Pigment Cell & Melanoma Research. PMID 26471867 DOI: 10.1111/Pcmr.12431 |
0.338 |
|
| 2015 |
Freiberger SN, Cheng PF, Iotzova-Weiss G, Neu J, Liu Q, Dziunycz P, Zibert JR, Dummer R, Skak K, Levesque MP, Hofbauer GF. Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2. Molecular Cancer Therapeutics. 14: 2132-42. PMID 26116359 DOI: 10.1158/1535-7163.Mct-15-0023-T |
0.383 |
|
| 2015 |
Kim H, Frederick DT, Levesque MP, Cooper ZA, Feng Y, Krepler C, Brill L, Samuels Y, Hayward NK, Perlina A, Piris A, Zhang T, Halaban R, Herlyn MM, Brown KM, et al. Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Reports. 11: 1458-73. PMID 26027934 DOI: 10.1016/J.Celrep.2015.04.049 |
0.358 |
|
| 2015 |
Cheng PF, Shakhova O, Widmer DS, Eichhoff OM, Zingg D, Frommel SC, Belloni B, Raaijmakers MI, Goldinger SM, Santoro R, Hemmi S, Sommer L, Dummer R, Levesque MP. Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. Genome Biology. 16: 42. PMID 25885555 DOI: 10.1186/S13059-015-0594-4 |
0.348 |
|
| 2015 |
Otsuka A, Levesque MP, Dummer R, Kabashima K. Hedgehog signaling in basal cell carcinoma. Journal of Dermatological Science. 78: 95-100. PMID 25766766 DOI: 10.1016/J.Jdermsci.2015.02.007 |
0.379 |
|
| 2015 |
Raaijmakers MI, Widmer DS, Maudrich M, Koch T, Langer A, Flace A, Schnyder C, Dummer R, Levesque MP. A new live-cell biobank workflow efficiently recovers heterogeneous melanoma cells from native biopsies. Experimental Dermatology. 24: 377-80. PMID 25739758 DOI: 10.1111/Exd.12683 |
0.324 |
|
| 2015 |
Shakhova O, Cheng P, Mishra PJ, Zingg D, Schaefer SM, Debbache J, Häusel J, Matter C, Guo T, Davis S, Meltzer P, Mihic-Probst D, Moch H, Wegner M, Merlino G, ... Levesque MP, et al. Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma. Plos Genetics. 11: e1004877. PMID 25629959 DOI: 10.1371/Journal.Pgen.1004877 |
0.381 |
|
| 2015 |
Zingg D, Debbache J, Schaefer SM, Tuncer E, Frommel SC, Cheng P, Arenas-Ramirez N, Haeusel J, Zhang Y, Bonalli M, McCabe MT, Creasy CL, Levesque MP, Boyman O, Santoro R, et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nature Communications. 6: 6051. PMID 25609585 DOI: 10.1038/Ncomms7051 |
0.355 |
|
| 2015 |
Otsuka A, Dreier J, Cheng PF, Nägeli M, Lehmann H, Felderer L, Frew IJ, Matsushita S, Levesque MP, Dummer R. Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1289-97. PMID 25593302 DOI: 10.1158/1078-0432.Ccr-14-2110 |
0.33 |
|
| 2015 |
Goldinger SM, Mangana J, Frauchiger AL, Kaufmann C, Held U, Von Moos R, Romano E, Michielin O, Levesque MP, Dummer R. Real life experience with check point and kinase inhibitors in Swiss advanced melanoma patients. Journal of Clinical Oncology. 33: e20064-e20064. DOI: 10.1200/Jco.2015.33.15_Suppl.E20064 |
0.329 |
|
| 2015 |
Otsuka A, Dreier J, Cheng P, Nägeli M, Levesque MP, Dummer R. 3349 Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31867-6 |
0.319 |
|
| 2014 |
Venturelli S, Sinnberg TW, Berger A, Noor S, Levesque MP, Böcker A, Niessner H, Lauer UM, Bitzer M, Garbe C, Busch C. Epigenetic impacts of ascorbate on human metastatic melanoma cells. Frontiers in Oncology. 4: 227. PMID 25202679 DOI: 10.3389/Fonc.2014.00227 |
0.313 |
|
| 2014 |
Dummer R, Goldinger SM, Widmer D, Dreier J, Levesque MP. To B-(RAF) or not to be. The Journal of Investigative Dermatology. 134: 1200-1. PMID 24732335 DOI: 10.1038/Jid.2014.62 |
0.307 |
|
| 2013 |
Widmer DS, Hoek KS, Cheng PF, Eichhoff OM, Biedermann T, Raaijmakers MI, Hemmi S, Dummer R, Levesque MP. Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching. The Journal of Investigative Dermatology. 133: 2436-43. PMID 23474946 DOI: 10.1038/Jid.2013.115 |
0.371 |
|
| 2013 |
Raaijmakers MI, Rozati S, Goldinger SM, Widmer DS, Dummer R, Levesque MP. Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy. 5: 169-82. PMID 23413908 DOI: 10.2217/Imt.12.162 |
0.304 |
|
| 2013 |
Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 494: 251-5. PMID 23302800 DOI: 10.1038/Nature11814 |
0.305 |
|
| 2013 |
McMahon M, Thakur MD, Marsh V, Silva J, Landman A, Deuker M, Salangsang F, Pryer N, Phillips W, Levesque M, Dummer R, Bosenberg M, Sellers WR, Stuart D. Abstract SY17-03: Targeting BRAF and PI3′-kinase signaling for therapy of melanoma. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Sy17-03 |
0.38 |
|
| 2013 |
Thakur MD, Fisher R, Salangsang F, Landman A, Sellers W, Pryer N, Levesque MP, Dummer R, Gore M, Larkin J, McMahon M, Stuart D. Abstract LB-144: Modeling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-144 |
0.345 |
|
| 2012 |
Baumbach J, Levesque MP, Raff JW. Centrosome loss or amplification does not dramatically perturb global gene expression in Drosophila. Biology Open. 1: 983-93. PMID 23213376 DOI: 10.1242/Bio.20122238 |
0.316 |
|
| 2012 |
Chen YY, Harris MP, Levesque MP, Nüsslein-Volhard C, Sonawane M. Heterogeneity across the dorso-ventral axis in zebrafish EVL is regulated by a novel module consisting of sox, snail1a and max genes. Mechanisms of Development. 129: 13-23. PMID 22522081 DOI: 10.1016/J.Mod.2012.03.003 |
0.326 |
|
| 2012 |
Mangana J, Levesque MP, Karpova MB, Dummer R. Sorafenib in melanoma. Expert Opinion On Investigational Drugs. 21: 557-68. PMID 22394203 DOI: 10.1517/13543784.2012.665872 |
0.309 |
|
| 2010 |
De Smet I, Lau S, Voss U, Vanneste S, Benjamins R, Rademacher EH, Schlereth A, De Rybel B, Vassileva V, Grunewald W, Naudts M, Levesque MP, Ehrismann JS, Inzé D, Luschnig C, et al. Bimodular auxin response controls organogenesis in Arabidopsis. Proceedings of the National Academy of Sciences of the United States of America. 107: 2705-10. PMID 20133796 DOI: 10.1073/Pnas.0915001107 |
0.551 |
|
| 2009 |
Reischauer S, Levesque MP, Nüsslein-Volhard C, Sonawane M. Lgl2 executes its function as a tumor suppressor by regulating ErbB signaling in the zebrafish epidermis. Plos Genetics. 5: e1000720. PMID 19911055 DOI: 10.1371/Journal.Pgen.1000720 |
0.38 |
|
| 2008 |
De Smet I, Vassileva V, De Rybel B, Levesque MP, Grunewald W, Van Damme D, Van Noorden G, Naudts M, Van Isterdael G, De Clercq R, Wang JY, Meuli N, Vanneste S, Friml J, Hilson P, et al. Receptor-like kinase ACR4 restricts formative cell divisions in the Arabidopsis root. Science (New York, N.Y.). 322: 594-7. PMID 18948541 DOI: 10.1126/Science.1160158 |
0.57 |
|
| 2008 |
Swarup K, Benková E, Swarup R, Casimiro I, Péret B, Yang Y, Parry G, Nielsen E, De Smet I, Vanneste S, Levesque MP, Carrier D, James N, Calvo V, Ljung K, et al. The auxin influx carrier LAX3 promotes lateral root emergence. Nature Cell Biology. 10: 946-54. PMID 18622388 DOI: 10.1038/Ncb1754 |
0.522 |
|
| 2008 |
Dohmann EM, Levesque MP, Isono E, Schmid M, Schwechheimer C. Auxin responses in mutants of the Arabidopsis CONSTITUTIVE PHOTOMORPHOGENIC9 signalosome. Plant Physiology. 147: 1369-79. PMID 18467458 DOI: 10.1104/Pp.108.121061 |
0.306 |
|
| 2007 |
Cui H, Levesque MP, Vernoux T, Jung JW, Paquette AJ, Gallagher KL, Wang JY, Blilou I, Scheres B, Benfey PN. An evolutionarily conserved mechanism delimiting SHR movement defines a single layer of endodermis in plants. Science (New York, N.Y.). 316: 421-5. PMID 17446396 DOI: 10.1126/Science.1139531 |
0.702 |
|
| 2006 |
Levesque MP, Vernoux T, Busch W, Cui H, Wang JY, Blilou I, Hassan H, Nakajima K, Matsumoto N, Lohmann JU, Scheres B, Benfey PN. Whole-genome analysis of the SHORT-ROOT developmental pathway in Arabidopsis. Plos Biology. 4: e143. PMID 16640459 DOI: 10.1371/Journal.Pbio.0040143 |
0.744 |
|
| 2006 |
Levesque MP, Vernoux T, Busch W, Cui H, Wang JY, Blilou I, Hassan H, Nakajima K, Matsumoto N, Lohmann JU, Scheres B, Benfey PN. Correction: Whole-Genome Analysis of the SHORT-ROOT Developmental Pathway in Arabidopsis Plos Biology. 4: e249. DOI: 10.1371/Journal.Pbio.0040249 |
0.702 |
|
| 2005 |
Lee JY, Levesque M, Benfey PN. High-throughput RNA isolation technologies. New tools for high-resolution gene expression profiling in plant systems. Plant Physiology. 138: 585-90. PMID 15955922 DOI: 10.1104/Pp.105.061812 |
0.577 |
|
| 2004 |
Levesque MP, Benfey PN. Systems biology. Current Biology : Cb. 14: R179-80. PMID 15028228 DOI: 10.1016/j.cub.2004.02.012 |
0.41 |
|
| 2003 |
Levesque M, Shasha D, Kim W, Surette MG, Benfey PN. Trait-to-gene: a computational method for predicting the function of uncharacterized genes. Current Biology : Cb. 13: 129-33. PMID 12546786 DOI: 10.1016/S0960-9822(03)00009-5 |
0.437 |
|
| Show low-probability matches. |